Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial

Journal of Clinical Oncology

Volumn 20, Issue 8, 2002, Pages 2045-2052

  Eton, Omar ^a   Legha, Sewa S ^a   Bedikian, Agop Y ^a   Lee, J Jack ^a   Buzaid, Antonio C ^a   Hodges, Cynthia ^a   Ring, Sigrid E ^a   Papadopoulos, Nicholas E ^a   Plager, Carl ^a   East, Mary Jo ^a   Zhan, Feng ^a   Benjamin, Robert S ^a  

^a HOSPITAL SÍRIO LIBANÊS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DACARBAZINE; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2; VINBLASTINE;

ACUTE PANCREATITIS; ADULT; ANOREXIA; ARTICLE; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; GRAND MAL EPILEPSY; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SEPSIS; SOMNOLENCE; STOMATITIS; SURVIVAL TIME; VOMITING;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL RESPONSE MODIFIERS; CISPLATIN; DACARBAZINE; FEMALE; HUMANS; INTERFERON ALFA-2B; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; SURVIVAL ANALYSIS; VINBLASTINE;

EID: 0037089629     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.07.044     Document Type: Article

References (19)

1. Prognostic factors for survival of patients treated systemically for disseminated melanoma
2. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma
3. Cisplatin, vinblastine, and dacarbazine (CVD) versus DTIC alone in metastatic melanoma: Preliminary results of a phase III cancer community oncology program (CCOP) trial
4. Phase II study of recombinant alpha-interferon in malignant melanoma
5. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update
6. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alpha- 2a in patients with advanced melanoma
7. Phase II trial of recombinant human interleukin-2 and interferon alpha-2a: Implications for the treatment of patients with metastatic melanoma
8. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha
9. Development and results of biochemotherapy in metastatic melanoma: The University of Texas M. D. Anderson Cancer Center experience
10. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alpha, and interleukin- 2 for patients with metastatic melanoma
11. Combination of chemotherapy with interleukin-2 and interferon-alpha for the treatment of metastatic melanoma
12. Salpetriere Hospital experience with biochemotherapy in metastatic melanoma
13. Nonparametric estimation from incomplete observations
14. General design issues in efficacy, equivalency and superiority trials
15. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alpha- 2b
16. Chemotherapy and cytokine-based immunotherapy for high-risk and metastatic melanoma
17. Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma